Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Chemocentryx Inc (CCXI)

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,709,799
  • Shares Outstanding, K 71,356
  • Annual Sales, $ 32,220 K
  • Annual Income, $ -131,760 K
  • 60-Month Beta 1.22
  • Price/Sales 115.06
  • Price/Cash Flow N/A
  • Price/Book 15.68
Trade CCXI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings -0.44 on 08/09/22
  • Next Earnings Date 11/08/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 2.40%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.42
  • Number of Estimates 7
  • High Estimate -0.28
  • Low Estimate -0.53
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.55 +0.85%
on 09/23/22
52.00 -0.02%
on 10/19/22
+0.43 (+0.83%)
since 09/19/22
3-Month
21.87 +137.72%
on 07/25/22
52.00 -0.02%
on 10/19/22
+28.45 (+120.86%)
since 07/19/22
52-Week
14.95 +247.76%
on 05/09/22
52.00 -0.02%
on 10/19/22
+18.34 (+54.50%)
since 10/19/21

Most Recent Stories

More News
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

PBE : 68.03 (+1.74%)
VRTX : 321.37 (+0.19%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
CTLT : 52.25 (+0.04%)
XBI : 85.66 (+3.09%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 85.66 (+3.09%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
GBT : 68.49 (+0.01%)
FBT : 159.04 (+1.53%)
KRTX : 236.82 (+2.97%)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 85.66 (+3.09%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
GBT : 68.49 (+0.01%)
FBT : 159.04 (+1.53%)
KRTX : 236.82 (+2.97%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 68.03 (+1.74%)
VRTX : 321.37 (+0.19%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
CTLT : 52.25 (+0.04%)
XBI : 85.66 (+3.09%)
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:...

AMGN : 285.51 (-0.15%)
CCXI : 51.99 (+0.06%)
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

CCXI : 51.99 (+0.06%)
EIGR : 4.53 (+0.44%)
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

PBE : 68.03 (+1.74%)
VRTX : 321.37 (+0.19%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
CTLT : 52.25 (+0.04%)
XBI : 85.66 (+3.09%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 85.66 (+3.09%)
IBB : 138.43 (+0.93%)
CCXI : 51.99 (+0.06%)
GBT : 68.49 (+0.01%)
FBT : 159.04 (+1.53%)
KRTX : 236.82 (+2.97%)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CYBE, CCXI, AVLR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CYBE : 54.00 (unch)
CCXI : 51.99 (+0.06%)
AVLR : 93.48 (+0.03%)
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”)...

CCXI : 51.99 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ChemoCentryx, Inc., being a clinical-stage biopharmaceutical company, focuses on discovering, developing and commercializing orally-administered medications targeted at autoimmune diseases, inflammatory disorders & cancer. Its lead drug, avacopan, is recognized as an adjunctive treatment combined with...

See More

Key Turning Points

3rd Resistance Point 52.02
2nd Resistance Point 52.01
1st Resistance Point 52.00
Last Price 51.99
1st Support Level 51.98
2nd Support Level 51.97
3rd Support Level 51.96

See More

52-Week High 52.00
Last Price 51.99
Fibonacci 61.8% 37.85
Fibonacci 50% 33.47
Fibonacci 38.2% 29.10
52-Week Low 14.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar